1. Home
  2. THH vs FULC Comparison

THH vs FULC Comparison

Compare THH & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THH
  • FULC
  • Stock Information
  • Founded
  • THH 2013
  • FULC 2015
  • Country
  • THH Japan
  • FULC United States
  • Employees
  • THH N/A
  • FULC N/A
  • Industry
  • THH
  • FULC Biotechnology: Pharmaceutical Preparations
  • Sector
  • THH
  • FULC Health Care
  • Exchange
  • THH Nasdaq
  • FULC Nasdaq
  • Market Cap
  • THH 414.9M
  • FULC 468.1M
  • IPO Year
  • THH 2025
  • FULC 2019
  • Fundamental
  • Price
  • THH $9.81
  • FULC $11.57
  • Analyst Decision
  • THH
  • FULC Strong Buy
  • Analyst Count
  • THH 0
  • FULC 7
  • Target Price
  • THH N/A
  • FULC $12.71
  • AVG Volume (30 Days)
  • THH 49.2K
  • FULC 926.2K
  • Earning Date
  • THH 12-05-2025
  • FULC 10-29-2025
  • Dividend Yield
  • THH N/A
  • FULC N/A
  • EPS Growth
  • THH N/A
  • FULC N/A
  • EPS
  • THH 0.00
  • FULC N/A
  • Revenue
  • THH $24,528,835.00
  • FULC N/A
  • Revenue This Year
  • THH N/A
  • FULC N/A
  • Revenue Next Year
  • THH N/A
  • FULC N/A
  • P/E Ratio
  • THH $4,864.29
  • FULC N/A
  • Revenue Growth
  • THH 2.24
  • FULC 2752.05
  • 52 Week Low
  • THH $4.20
  • FULC $2.32
  • 52 Week High
  • THH $12.00
  • FULC $12.19
  • Technical
  • Relative Strength Index (RSI)
  • THH N/A
  • FULC 68.33
  • Support Level
  • THH N/A
  • FULC $10.75
  • Resistance Level
  • THH N/A
  • FULC $12.05
  • Average True Range (ATR)
  • THH 0.00
  • FULC 0.76
  • MACD
  • THH 0.00
  • FULC 0.35
  • Stochastic Oscillator
  • THH 0.00
  • FULC 87.20

About THH TryHard Holdings Limited Ordinary Shares

Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Share on Social Networks: